YBL-016

N/A

Report date: 2023/03/08 11:24:48

Base Information

Drug NameYBL-016

Drug Alias NameYBL-016

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed death-ligand 1 blockers +[4]

TargetsProgrammed death-ligand 1Interleukin-10

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesY-biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesY-biologics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A